文献速递妇科

经宫颈子宫肌瘤消融术与微创子宫肌瘤剔除术治疗症状性子宫肌瘤的术后恢复:一项随机对照试验

Recovery After Transcervical Fibroid Ablation Versus Minimally Invasive Myomectomy for Symptomatic Uterine Fibroids: A Randomised Controlled Trial.
PubMed 文献 · BJOG · 2025-11-10

在德国蒂宾根大学医院开展的随机对照试验,纳入144例症状性子宫肌瘤的绝经前女性,比较经宫颈子宫肌瘤消融术(TFA)与微创子宫肌瘤剔除术(MIM)的早期恢复结局。TFA组恢复日常活动的中位时间短于MIM组(5.5天 vs 13天,log-rank P<0.001),手术时间、术后疼痛、阿片类药物使用及出院准备时间均优于MIM,短期安全性相当。

要点

  • TFA组恢复日常活动中位时间5.5天,MIM组13天(log-rank P<0.001)。
  • TFA组手术时间、术后疼痛、阿片类药物使用比例及出院准备时间均优于MIM。
  • 10项恢复指标中9项统计学支持TFA,无一项支持MIM;MIM组发生1例严重不良事件。

核心结论

  • 对于症状性子宫肌瘤的治疗,TFA较MIM恢复更快,短期安全性相当。

研究设计与样本

  • 随机对照试验,在德国蒂宾根大学医院开展,纳入18-50岁症状性子宫肌瘤的绝经前女性,随机接受TFA或MIM,MIM组合并黏膜下肌瘤时同时行宫腔镜子宫肌瘤剔除术。
  • 144例随机患者中119例提供随访数据(TFA组58例,MIM组61例),报告至7周随访的临床结局。

主要发现

  • 主要终点达到,恢复日常活动中位时间TFA组5.5天 vs MIM组13天(log-rank P<0.001)。
  • 手术时间TFA组51±21分钟 vs MIM组95±37分钟(P<0.001)。
  • 出院准备时间TFA组22.9±13.2小时 vs MIM组58.9±33.1小时(P<0.001)。
  • 阿片类药物使用TFA组25.9% vs MIM组49.2%(P=0.009)。
  • 术后至出院期间疼痛所有比较均P<0.01,支持TFA;10项恢复指标中9项统计学支持TFA,无一项支持MIM;MIM组发生1例严重不良事件(因术后出血行诊断性腹腔镜)。

临床怎么用

  • 原文结论为TFA较MIM恢复更快且短期安全性相当,未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate early recovery outcomes with transcervical fibroid ablation (TFA) compared to minimally invasive myomectomy (MIM) in women with symptomatic uterine fibroids. DESIGN: Randomised controlled trial. SETTING: Tübingen University Hospital (Tübingen, Germany). SAMPLE: Premenopausal women aged 18-50 years with symptomatic uterine fibroids. METHODS: Participants were randomised to undergo TFA or MIM. The MIM group underwent laparoscopic myomectomy with concurrent hysteroscopic myomectomy if submucosal fibroids were present. MAIN OUTCOME MEASURES: The primary endpoint was the time to return to normal activities. Secondary outcomes included procedure time, postprocedural pain, hospital discharge readiness, time to return to 10 additional activities of daily living, and adverse events. Clinical outcomes through 7 weeks of follow-up were reported. The primary endpoint was evaluated at p < 0.028 due to a pre-planned interim analysis; secondary outcomes were evaluated at p < 0.05. RESULTS: Among 144 randomised patients, 119 provided follow-up data (58 TFA; 61 MIM). The primary endpoint was met with the median time to return to normal activities favouring TFA (5.5 vs. 13 days; log-rank p < 0.001). Procedure time (51 ± 21 vs. 95 ± 37 min; p < 0.001), postprocedural pain through discharge (all p < 0.01), opioid utilisation (25.9% vs. 49.2%, p = 0.009), and time to discharge readiness (22.9 ± 13.2 vs. 58.9 ± 33.1 h; p < 0.001) favoured TFA. Nine of 10 treatment recovery metrics statistically favoured TFA with none favouring MIM. One serious adverse event occurred in a patient treated with MIM (diagnostic laparoscopy for postoperative bleeding). CONCLUSIONS: TFA offers a faster recovery than MIM for the treatment of symptomatic uterine fibroids, with a comparable short-term safety profile. TRIAL REGISTRATION: This trial was prospectively registered on the German Clinical Trials Register; https://drks.de/search/de/trial/DRKS00028847.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Neis F, Kraemer B, Bauer A, et al. Recovery After Transcervical Fibroid Ablation Versus Minimally Invasive Myomectomy for Symptomatic Uterine Fibroids: A Randomised Controlled Trial. BJOG. 2025. PMID: 41208417. doi:10.1111/1471-0528.70081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。